Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

Abstract: A mobile device includes a first display portion, a second display portion and a graphics processor. The first display portion is viewable while the second display portion is obscured when the mobile device is in a retracted configuration. Both display portions are viewable when the mobile device is in an expanded configuration. The graphics processor may be coupled to each display portion and configured to generate a first image for display on: the first display portion when the mobile device is in the retracted configuration; at least one of the display portions while the mobile device is in the expanded configuration; and at least one of the display portions while the mobile device transitions between the retracted configuration and the expanded configuration. The second display portion may be a flexible display material, such as an OLED display and with the first display portion may be a single sheet OLED display.

Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

Abstract: A mobile device includes a first display portion, a second display portion and a graphics processor. The first display portion is viewable while the second display portion is obscured when the mobile device is in a retracted configuration. Both display portions are viewable when the mobile device is in an expanded configuration. The graphics processor may be coupled to each display portion and configured to generate a first image for display on: the first display portion when the mobile device is in the retracted configuration; at least one of the display portions while the mobile device is in the expanded configuration; and at least one of the display portions while the mobile device transitions between the retracted configuration and the expanded configuration. The second display portion may be a flexible display material, such as an OLED display and with the first display portion may be a single sheet OLED display.

Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Abstract: A mobile device includes a first display portion, a second display portion and a graphics processor. The first display portion is viewable while the second display portion is obscured when the mobile device is in a retracted configuration. Both display portions are viewable when the mobile device is in an expanded configuration. The graphics processor may be coupled to each display portion and configured to generate a first image for display on: the first display portion when the mobile device is in the retracted configuration; at least one of the display portions while the mobile device is in the expanded configuration; and at least one of the display portions while the mobile device transitions between the retracted configuration and the expanded configuration. The second display portion may be a flexible display material, such as an OLED display and with the first display portion may be a single sheet OLED display.

Abstract: The present invention comprises compounds of Formula I. wherein: R1, Q, R3, R4, R5, R6, A1, and A2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Abstract: The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

Abstract: Content receivers may simultaneously record multiple instances of content for multiple programming channels based on content provider instructions. Systems and methods utilize the content receivers to record these multiple instances from at least a single transponder. In some instances, multiple transponders may have a common control word so that content carried on each such transponder may be simultaneously received, decoded and recorded. Further, a single demodulator may be associated with multiple tuners, so that the single demodulator processes all content received from transponders with common control words and/or other encryption mechanisms.

Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Abstract: The present invention comprises compounds of Formula I. wherein: R1, Q, R3, R4, R5, R6, A1, and A2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Abstract: The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Abstract: A portable communications device includes a first screen and a second screen. A third screen may be provided. The device includes a housing into in and from which each of the second and/or third screens may be retracted and extended. When retracted, outer edges of the second and/or third screens encase opposing sides of the first screen. A cavity in the housing is provided into which the second and third screens may be retracted. Track mechanisms and bearing mechanisms may support and facilitate extension and retraction of the second and third screens. Spring mechanisms facilitate alignment of the first, second and third screens. Holding and/or cooperative release mechanisms may be used to respectively hold and release the second and third screens within the housing.

Abstract: A method for creating an announcement stream for a geographic region is provided. The method receives, at a designated computer system, characterizing metadata for a first audio/video stream; analyzes a second audio/video stream to obtain characterizing metadata for the second video stream; compares, with the computer system, the characterizing metadata for the first video stream to the characterizing metadata for the second video stream to generate offset data; and calculates timing information corresponding to segment boundaries for the second video stream using the offset data.

Abstract: A method for creating an announcement stream for a geographic region is provided. The method receives, at a designated computer system, characterizing metadata for a first audio/video stream; analyzes a second audio/video stream to obtain characterizing metadata for the second video stream; compares, with the computer system, the characterizing metadata for the first video stream to the characterizing metadata for the second video stream to generate offset data ; and calculates timing information corresponding to segment boundaries for the second video stream using the offset data.